V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 240001797 | 240010723 | 0 | 112.2 | null | 2019-03-30 | 2019-06-06 | Hydroxycarbamide | 02 | N | HYDROXYCARBAMIDE | 100589970 |
| 240001816 | 240010726 | 1.87 | 91.1 | null | null | 2020-06-06 | null | null | null | RITUXIMAB | 101132644 |
| 240001818 | 240010727 | 1.68 | 22.3 | null | null | 2021-10-21 | null | null | null | TRIAL UNSPECIFIED | 101189206 |
| 240001837 | 240010729 | 1.7 | 57 | null | null | 2022-03-30 | null | 02 | null | AZACITIDINE | 100257094 |
| 240001869 | 240010732 | 1.8 | 76.5 | Palliative (P) | 2018-12-13 | 2018-12-14 | Hydroxycarbamide | 02 | N | HYDROXYCARBAMIDE | 101123947 |
| 240001880 | 240010734 | 1.71 | 110.9 | null | null | 2020-06-20 | null | null | N | METHOTREXATE | 100432978 |
| 240001888 | 240010736 | null | null | 03 | 2021-09-22 | 2021-09-24 | Hydroxycarbamide | 02 | N | HYDROXYCARBAMIDE | 100524121 |
| 240001895 | 240010738 | 1.76 | 100 | null | null | 2020-01-22 | null | 02 | null | RITUXIMAB | 100246995 |
| 240001912 | 240010740 | 1.68 | 91.5 | Curative (C) | null | 2022-01-01 | GEMTUZUMAB OZOGAMICIN | N | null | FLAG + IDARUBICIN | 100060591 |
| 240001998 | 240010746 | null | null | null | 2022-03-22 | 2022-03-30 | null | 02 | null | CYTARABINE + ETOPOSIDE + LOMUSTINE + MELPHALAN | 101132119 |
| 240002008 | 240010748 | 1.66 | 15 | null | 2019-04-02 | 2019-04-13 | IMATINIB | N | null | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 100372179 |
| 240002033 | 240010751 | null | 80.6 | 03 | 2022-02-15 | 2022-02-15 | Imatinib 400mg | 02 | N | NOT MATCHED | 101812728 |
| 240002034 | 240010752 | 1.82 | 9.5 | Palliative (P) | null | 2019-08-31 | CYCLOPHOSPHAMIDE + FLUDARABINE | null | N | AML INTERIM GUIDELINES FLAG-IDA | 100494626 |
| 240002062 | 240010757 | 1.77 | 79 | Curative (C) | null | 2021-12-16 | CYTARABINE + DAUNORUBICIN + Gemtuzumab Ozogamicin | null | N | TRANSPLANT CYCLOPHOSPHAMIDE + FLUDARABINE (+/- TBI) | 101172936 |
| 240002093 | 240010760 | 1.8 | 54.5 | Curative (C) | 2016-12-27 | 2017-02-07 | R-GDP | N | N | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 100488667 |
| 240002110 | 240010762 | 1.6 | 83.2 | null | null | 2017-09-08 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | N | null | CYTARABINE + DAUNORUBICIN | 100107521 |
| 240002144 | 240010764 | 1.72 | 68.9 | null | 2022-01-02 | 2022-01-03 | null | 02 | null | AML MYECHILD 01 FLA-IDARUBICIN | 100133154 |
| 240002152 | 240010765 | 1.65 | 28.5 | null | 2019-12-19 | 2019-12-19 | Brentuximab Vedotin | 02 | null | PEG INTERFERON | 100343792 |
| 240002160 | 240010768 | 1.74 | 70.2 | Curative (C) | 2016-06-08 | 2016-06-08 | LENALIDOMIDE | 01 | null | AML INTERIM GUIDELINES FLAG-IDA | 100300505 |
| 240002189 | 240010773 | 1.83 | 16.8 | Curative (C) | null | 2020-05-09 | ESHAP R | null | N | LEAM | 100197632 |
| 240002228 | 240010778 | 1.77 | 60 | Palliative (P) | 2020-04-16 | 2020-04-17 | AML MyeChild 01 A Mitozantrone/Cytarabine | 02 | N | DA | 101252329 |
| 240002248 | 240010780 | 1.88 | 83.8 | Disease modification (D) | 2016-06-06 | 2016-06-08 | AML Downs haM | 02 | null | DA | 100581147 |
| 240002253 | 240010781 | 0 | 0 | Disease modification (D) | 2018-09-14 | 2018-09-16 | null | 02 | N | AML16 TRIAL | 100254580 |
| 240002282 | 240010784 | 1.8 | 67.3 | Curative (C) | 2019-10-12 | 2019-10-12 | null | Y | N | ANAGRELIDE | 101256721 |
| 240002287 | 240010785 | 1.7 | 61 | null | 2017-01-22 | 2017-02-01 | Quizartinib | 02 | null | CYTARABINE + ETOPOSIDE + IFOSFAMIDE | 101567333 |
| 240002298 | 240010786 | 1.66 | 104 | null | 2021-10-16 | 2021-10-20 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | null | TRANSPLANT BUSULFAN + FLUDARABINE | 100054492 |
| 240002310 | 240010787 | 1.86 | 59.6 | null | null | 2022-02-05 | AML MyeChild 01 FLA | null | null | TRANSPLANT ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 100045573 |
| 240002311 | 240010788 | 1.76 | 41.4 | Adjuvant (A) | 2019-05-04 | 2019-05-05 | AML MyeChild 01 Triple IT | 02 | N | METHOTREXATE INTRATHECAL | 101215538 |
| 240002316 | 240010789 | 0 | 35 | Palliative (P) | null | 2020-12-18 | null | 02 | null | FCR | 100992913 |
| 240002344 | 240010792 | 1.7 | 54.9 | Curative (C) | 2020-07-27 | 2020-07-27 | IBRUTINIB | 02 | N | VENETOCLAX | 101583614 |
| 240002345 | 240010793 | 1.62 | 96.9 | Palliative (P) | null | 2021-05-01 | Cytarabine High Dose | null | N | AML MYECHILD 01 IT CYT | 100710683 |
| 240002350 | 240010794 | 1.63 | 50 | Curative (C) | null | 2019-10-31 | Cyclophosphamide+Fludara+TBI Allo | null | N | TRIAL | 101108568 |
| 240002351 | 240010795 | 1.59 | 53.9 | null | 2018-03-25 | 2018-04-01 | null | N | null | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100578083 |
| 240002365 | 240010796 | 1.8 | 113.6 | Curative (C) | 2016-09-19 | 2016-09-27 | Cytarabine High Dose | 02 | N | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 101217456 |
| 240002374 | 240010797 | 1.82 | 73.2 | Palliative (P) | 2020-01-01 | 2020-01-01 | null | 01 | N | AML MYECHILD 01 HD ARAC | 100187681 |
| 240002384 | 240010798 | 1.62 | 82.9 | Curative (C) | null | 2021-01-09 | Venetoclax | null | null | AML INTERIM GUIDELINES FLAG-IDA | 101289571 |
| 240002391 | 240010799 | 1.7 | 17.15 | null | null | 2020-12-17 | CNS LGG2004 03 vinc + carbo | null | null | UKALL14- MAINTENANCE | 101179262 |
| 240002393 | 240010800 | 1.77 | 66.3 | null | 2019-07-31 | 2019-08-04 | CVP R | 02 | null | NOT MATCHED | 100445404 |
| 240002408 | 240010801 | 1.61 | 79.4 | Curative (C) | 2019-09-18 | 2019-09-19 | Cyclophosphamide+Fludara+TBI Allo | 02 | null | RUXOLITINIB | 101831406 |
| 240002415 | 240010802 | 1.65 | 97.8 | null | 2019-03-02 | 2019-03-06 | AML MyeChild 01 Triple IT | 02 | null | CYTARABINE HIGH DOSE | 100564305 |
| 240002418 | 240010804 | 1.87 | 29.2 | Curative (C) | 2021-07-17 | 2021-07-20 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 100515222 |
| 240002421 | 240010805 | 1.69 | 74.4 | Curative (C) | 2021-07-08 | 2021-07-10 | CAR-T Yescarta + Fludarabine + Cyclophosphamide | 01 | N | NOT MATCHED | 100148329 |
| 240002424 | 240010806 | 1.65 | 52.9 | Curative (C) | 2022-01-28 | 2022-01-29 | Cyclophosphamide + Dex + Rituximab | 02 | null | ALL INT GDE 2019 MAINTENANCE | 100682624 |
| 240002427 | 240010807 | 1.5 | 79 | null | 2019-10-02 | 2019-10-02 | ALL Relapse Induction A | 02 | null | OBINUTUZUMAB + VENETOCLAX | 100828896 |
| 240002428 | 240010808 | 1.8 | null | Not known (9) | 2016-11-15 | 2016-11-21 | R IVAC | 02 | null | TRANSPLANT ALEMTUZUMAB + CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 101526696 |
| 240002431 | 240010810 | 1.61 | 96.5 | Disease modification (D) | 2020-05-24 | 2020-05-25 | AML Downs AIE | 02 | N | BLEOMYCIN + CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + PROCARBAZINE + VINCRISTINE | 101729725 |
| 240002447 | 240010811 | 1.6 | 86 | Palliative (P) | 2017-06-15 | 2017-09-11 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | null | CYTARABINE + FLUDARABINE + IDARUBICIN | 100679385 |
| 240002448 | 240010812 | 1.58 | 138.9 | null | 2020-04-25 | 2020-06-07 | GDP | 02 | null | ALEMTUZUMAB + CYTARABINE + ETOPOSIDE + FLUDARABINE + LOMUSTINE + MELPHALAN | 100616707 |
| 240002454 | 240010813 | 1.88 | 88.5 | 03 | 2016-04-03 | 2016-12-27 | CYTARABINE + METHOTREXATE | null | N | BUSULFAN | 100455766 |
| 240002478 | 240010815 | 1.89 | 69.7 | null | 2019-01-09 | 2019-01-10 | null | 02 | null | CYTARABINE + DAUNORUBICIN | 100059700 |